Canaccord Genuity initiated coverage on AbbVie with a new price target
$ABBV
Biotechnology: Pharmaceutical Preparations
Health Care
Canaccord Genuity initiated coverage of AbbVie with a rating of Buy and set a new price target of $262.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/30/2026 | $234.00 | Neutral → Buy | BofA Securities |
| 4/21/2026 | $262.00 | Buy | Canaccord Genuity |
| 2/25/2026 | $260.00 | Outperform | RBC Capital Mkts |
| 2/20/2026 | $275.00 | Overweight | Barclays |
| 1/8/2026 | Outperform → Peer Perform | Wolfe Research | |
| 1/7/2026 | $240.00 | Neutral | UBS |
| 12/10/2025 | $265.00 | Hold → Buy | HSBC Securities |
| 11/13/2025 | $280.00 | Sector Outperform | Scotiabank |
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
11-K - AbbVie Inc. (0001551152) (Filer)
8-K - AbbVie Inc. (0001551152) (Filer)
SD - AbbVie Inc. (0001551152) (Filer)
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-44) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/12/2026. Application Category: BLA, Application Number: 761105, Application Classification:
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-15) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/12/2026. Application Category: BLA, Application Number: 761262, Application Classification:
Submission status for ABBVIE INC's drug DECNUPAZ (ORIG-1) with active ingredient PIVEKIMAB SUNIRINE-PVZY has changed to 'Approval' on 05/27/2026. Application Category: BLA, Application Number: 761460, Application Classification:
250 Women Entrepreneurs Have Been Selected to Join a Multi-Week Skill-Building, Mentorship, and Networking ProgramBOTOX® Cosmetic Will Award 20 Participants With $20,000 Grants Each to Help Take Their Business Dreams to the Next LevelIRVINE, Calif., June 24, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the 2026 cohort of entrepreneurs selected to participate in The Confidence Collective: Empowering Women Entrepreneurs, an ongoing initiative from BOTOX® Cosmetic dedicated to uplifting and investing in women businessowners. This year's cohort was selected from a highly competitive and t
Canada is the first country to approve a new botulinum neurotoxin serotype for aesthetic use Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for the temporary improvement in the appearance of glabellar linesBoey® offers a differentiated treatment option for many people who are curious about facial injectablesResults may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeksBOTOX Cosmetic® (onabotulinumtoxinA) is the only neurotoxin clinically tested for use following treatment with Boey®IRVINE, Calif., June 23, 2026 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE:AB
MAVIRET® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in adults and children aged 3 years and older.The approval gives clinicians an option to initiate treatment as soon as acute infection is confirmed, aiming to reduce delays in care and lower the risk of liver disease progression, cirrhosis and liver cancer.As the only treatment approved in the EU for both acute and chronic HCV infection, MAVIRET may help streamline care pathways and support broader efforts to advance HCV elimination goals.NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE
BofA Securities upgraded AbbVie from Neutral to Buy and set a new price target of $234.00
Canaccord Genuity initiated coverage of AbbVie with a rating of Buy and set a new price target of $262.00
RBC Capital Mkts initiated coverage of AbbVie with a rating of Outperform and set a new price target of $260.00
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme
Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseasesApogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitisApogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthmaApogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billionAbbVie
NORTH CHICAGO, Ill., June 18, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable August 14, 2026, to stockholders of record at the close of business on July 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges
Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent; These Results Include an Unfavorable Impact of $0.41 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $15.002 Billion, an Increase of 12.4 Percent on a Reported Basis or 10.3 Percent on an Operational Basis First-Quarter Global Net Revenues from the Immunology Portfolio Were $7.290 Billion, an Increase of 16.4 Percent on a Reported Basis, or 14.3 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.483 Billion; Global Rinvoq Net Revenues Were $2.119 Billion; Global Humira Net Revenu
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)